Medical News Today recently reported the FDA has approved a new drug used to treat malignant pleural mesothelioma, a rare cancer usually associated with asbestos exposure. The drug is called Alimta, or pemetrexed disodium, and it’s distributed by Eli Lilly and Company. Alimta is intended to be used along with cisplatin.

It’s further reported in a randomized clinical trial, patients receiving Alimta along with cisplatin lived an average of 12 months after the trial began, compared with nine months for those on cisplatin alone.